Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin Effect on platelet function and thrombus formation by Lev, Eli I et al.
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OBJECTIVES The goal of this study was to compare the antithrombotic effects of enoxaparin versus
unfractionated heparin (UFH) when combined with eptifibatide in acute coronary syndrome
(ACS) patients.
BACKGROUND An increasing number of high-risk ACS patients are treated with low-molecular-weight
heparin and a glycoprotein (GP) IIb/IIIa inhibitor. There is a paucity of data regarding the
antithrombotic properties of such a combination as compared with UFH and GP IIb/IIIa
inhibitors.
METHODS Twenty-six ACS patients scheduled to undergo coronary angiography were treated with
subcutaneous enoxaparin (n  13) or intravenous UFH (n  13). All patients received
eptifibatide just before coronary angiography. Antithrombotic effects were assessed as changes
in platelet-thrombus formation using the Badimon ex vivo perfusion chamber. Perfusions
were carried out at a high shear rate (HSR) and a low shear rate (LSR). Patients underwent
two perfusion studies: at baseline (under enoxaparin or UFH) and 10 min after the
eptifibatide bolus. Platelet function was evaluated by ADP-induced platelet aggregation and
the rapid platelet function analyzer.
RESULTS Both therapeutic combinations achieved a marked reduction in platelet aggregation after
eptifibatide (83% to 89.7% reduction in the enoxaparin-eptifibatide group and 77.8% to
85.5% reduction in the UFH-eptifibatide group, inter-group differences not significant). Both
groups also demonstrated marked reductions in thrombus formation, but the reductions
achieved in the enoxaparin-eptifibatide group were significantly higher than those achieved in
the UFH-eptifibatide group (HSR: 75.6% reduction vs. 63.9%, respectively, p  0.01; LSR:
79.7% reduction vs. 66.1%, respectively, p  0.0001).
CONCLUSIONS The combination of eptifibatide with enoxaparin appears to have a more potent antithrom-
botic effect than that of eptifibatide and UFH in the doses tested. (J Am Coll Cardiol 2004;
43:966–71) © 2004 by the American College of Cardiology Foundationd
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cntithrombotic treatment with aspirin and heparin—either
nfracionated (UFH) or low-molecular-weight heparin
LMWH)—represents the current standard of care for
atients hospitalized with an acute coronary syndrome
ACS) without ST-elevation (1,2). Low-molecular-weight
eparin has several advantages over UFH: it has a more
redictable anticoagulant effect with a higher ratio of
nti-factor Xa to anti-factor IIa activity (3), requires no
onitoring of anticoagulation, is resistant to inhibition by
ctivated platelets (4), and has a lower incidence of heparin-
nduced thrombocytopenia (5). In addition, the LMWH
noxaparin has been shown to have a significant clinical
dvantage over UFH in reducing the composite end point of
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harma Ltd. Israel, and by Schering-Plough Israel.AManuscript received August 19, 2003; accepted September 16, 2003.eath, myocardial infarction (MI), or need for urgent
evascularization in ACS patients (6,7).
The development of platelet glycoprotein (GP) IIb/IIIa
nhibitors has extended the therapeutic options for anti-
hrombotic and anti-platelet treatment in the ACS and
ercutaneous coronary intervention (PCI) setting. Glyco-
rotein IIb/IIIa inhibitors given to ACS patients and/or
atients undergoing PCI have been shown to significantly
educe the rate of ischemic complications (8–11). There-
ore, an increasing number of high-risk ACS patients are
reated with enoxaparin and a GP IIb/IIIa inhibitor, such as
ptifibatide.
Recently, the concept of combining LMWH with GP
Ib/IIIa inhibitor therapy has gained support (12–17). The
afety of this combination therapy has been demonstrated
hen using abciximab or eptifibatide and intravenous enox-
parin during PCI (12–14) and the combination of tirofiban
r eptifibatide given with subcutaneous enoxaparin to ACS
atients (15–17). Recent data also suggest that the combi-
ation of a GP IIb/IIIa inhibitor with enoxaparin has better
linical efficacy than the combination with UFH. In the
ntithrombotic Combination Using Tirofiban and Enox-
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March 17, 2004:966–71 Eptifibatide Combined With Enoxaparin or Heparinparin (ACUTE) II trial, therapy with tirofiban and enox-
parin was associated with a reduction in refractory ischemia
equiring urgent revascularization, as compared with UFH
nd tirofiban (16). Similar results were obtained in the
ntegrilin and Enoxaparin Randomized Assessment of
cute Coronary Syndrome Treatment (INTERACT) trial,
n which treatment of ACS patients with eptifibatide and
noxaparin was associated with decreased ischemia as de-
ected by continuous electrocardiographic monitoring (17).
espite the emerging clinical evidence, there is a paucity of
ata comparing the antithrombotic properties of the two
ombination treatments, apart from a trend toward reduced
nhibition of platelet aggregation when GP IIb/IIIa inhibitors
re administered with UFH (15,18,19). The aim of the current
tudy, therefore, was to compare the antithrombotic effects of
noxaparin versus UFH when combined with eptifibatide in
CS patients intended for coronary angiography.
ETHODS
atients. Twenty-six ACS patients scheduled to undergo
oronary angiography within 24 to 48 h of enrollment were
ncluded in the study. Acute coronary syndrome was defined
s unstable angina or non–ST-segment elevation MI, with
ymptoms presenting in the 24 h before admission. Exclu-
ion criteria were ST-segment elevation acute MI; history of
emorrhagic diathesis; any major surgery; gastrointestinal or
enitourinary bleeding within six weeks; history of stroke
ithin two years or a residual neurological deficit; concur-
ent administration of oral anticoagulants unless the pro-
hrombin time was 1.2 times control; thrombocytopenia
100,000 cells/l); hemoglobin level 14 g/dl; severe
ncontrolled hypertension (180/110); known hypersensi-
ivity to any component of eptifibatide, enoxaparin, or
FH; renal failure (creatinine level 2.5 mg/dl); or prior
se of a GP IIb/IIIa inhibitor within the previous month.
he study was approved by the Institutional Review Board
f the Rabin Medical Center, and informed consent was
btained from each patient.
tudy medications. The study was comprised of two groups
f consecutively enrolled patients. Group 1 (n  13), which
Abbreviations and Acronyms
ACS  acute coronary syndrome
ACT  activated clotting time
aPTT  activated partial thromboplastin time
GP  glycoprotein
HSR  high shear rate
LMWH  low-molecular-weight heparin
LSR  low shear rate
MI  myocardial infarction
PCI  percutaneous coronary intervention
RPFA  rapid platelet function analyzer
TAT  thrombin antithrombin complex
UFH  unfractionated heparinas enrolled first, received the combination of enoxaparin and tptifibatide, and group 2 (n 13) received the combination of
FH and eptifibatide. In group 1, the patients received
noxaparin at a 1 mg/kg dose, administered subcutaneously
very 12 h. After at least two enoxaparin injections, and 3 to
h after the last injection, the patients were taken to the
atheterization laboratory. Just before the angiography, after
btaining arterial access, eptifibatide was administered as an
ntravenous bolus of 180 g/kg, followed by 2.0 g/kg/min
nfusion over 18 to 24 h. In group 2, the patients received UFH
s a bolus of 70 U/kg intravenously and an infusion of 15 U/kg,
djusted every 8 h to achieve 1.5 to 2.5 times the control
ctivated partial thromboplastin time (aPTT) value (1), which
s 30 s at the Rabin Medical Center laboratory. Unfractionated
eparin was continued during the patient’s arrival at the
atheterization laboratory, arterial access gain, and perfor-
ance of the second perfusion chamber, as detailed below. It
as discontinued after the perfusion chamber. Before the
ngiography, after obtaining the arterial access, eptifibatide was
dministered in an identical manner to group 1. In the patients
ho underwent PCI in group 2, additional UFH boluses were
iven as necessary during PCI (after the perfusion chamber) to
aintain an activated clotting time (ACT) of 225 to 275 s.
Concomitant medical therapy included oral aspirin 200 mg
aily from admission time, given to all patients. In addition,
atients who underwent intracoronary stent deployment re-
eived clopidogrel at a dose of 75 mg daily for four weeks after
CI.
x vivo perfusion chamber. All patients underwent two
erfusion chamber studies. This design allows each patient to
erve as his own control. Immediately before each perfusion
tudy, blood was also collected for coagulation and platelet
unction tests. In group 1, the first perfusion chamber was
erformed 3 to 5 h after an enoxaparin injection, when
aximum anti-Factor Xa and anti-Factor IIa activities occur
4). The second chamber was also performed 3 to 5 h after an
noxaparin injection, and 10 min after the eptifibatide bolus,
ust before performing the angiography. In group 2, the first
erfusion chamber was performed at least 1 h after the UFH
olus and beginning of infusion. The second chamber was
erformed, similar to group 1, 10 min after the eptifibatide
olus, when the patient was still receiving UFH and just before
erforming the angiography.
Antithrombotic effects were assessed as changes in the
urface of the platelet thrombus formed on the Badimon
erfusion chamber. The perfusion chamber used in this
tudy has been extensively described elsewhere (20–22). In
rief, it consists of a cylindrical flow channel (1- or 2-mm
iameter, 2-cm length) that allows the flowing of blood,
umped directly from the patient, over an exposed throm-
ogenic surface. Perfusions were performed at rheologic
onditions of low (212/s) and high (1,690/s) shear rate.
hese local flow conditions mimic mild to moderately
tenotic coronary arteries, respectively. Our previous work
emonstrated that these rheologic conditions resulted in
onsistent levels of platelet deposition and thrombus forma-
ion (22,23).
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Eptifibatide Combined With Enoxaparin or Heparin March 17, 2004:966–71hrombogenic substrates and perfusion studies. To trig-
er thrombus formation, porcine aortic tunica media was used
s substrate. The substrates (25  10-mm sections) were
urgically prepared to simulate the degree of severe arterial
njury induced by PCI, as previously described (20,21). During
ach perfusion study, venous blood was circulated from the
atient directly through three flow chambers connected in
eries—one at low shear rate (LSR) and two at high shear rate
HSR). The perfusion chamber system was connected with
olyethylene tubing to the patient’s intravenous access and
istally to a peristaltic pump (Masterflex model 7013, Cole-
almer Inc., Vernon Hills, Illinois) calibrated to maintain the
elected blood flow. Perfusion time was 5 min in both studies.
ll the perfusion studies were performed at 37°C by placing
he chambers in a water bath.
valuation of thrombus formation. After perfusion, spec-
mens were removed from the chamber and immediately
xed in 4% phosphate-buffered para-formaldehyde. Speci-
ens were then transversely cut into 2- to 4-mm thick
ieces and paraffin embedded. Histologic sections (5 m)
rom each specimen were prepared and stained with two
ypes of stain: combined Masson’s trichrome-elastin, which
tains total thrombus, and a murine monoclonal anti-human
15–42 antibody, which reacts with fibrin polymer.
Morphometric analyses were conducted at 10-fold mag-
ification. Thrombus area was measured on each section by
omputerized planimetry using Image-Pro Plus software
Media Cybernetics, Silver Spring, Maryland). The results
f six sections were averaged to determine the total throm-
us and fibrin area for each chamber.
latelet function assessment and coagulation tests.
efore each of the perfusion studies, blood was collected in
acutainers containing D-Phe-Pro-Arg chloromethyl ke-
one dihydrochloride (PPACK). The samples were evalu-
ted for platelet function, as well as coagulation profile
aPTT), complete blood count, anti-factor Xa activity,
hrombin antithrombin complex (TAT), and prothrombin
ragment 1  2 (F1.2). Anti-factor Xa activity was quanti-
ed by the Coamatic Heparin kit (Chromogenix Instru-
entation, Milano, Italy). Thrombin antithrombin complex
nd F1.2 levels were measured by enzyme immunoassay kits
Enzygnost-Dade Behring, Liederbach, Germany). Platelet
unction was assessed by in vitro platelet aggregation and
he rapid platelet function analyzer (RPFA) (Accumetrics
nc., San Diego, California). Platelet aggregation was per-
ormed in platelet-rich plasma in response to 10 and 20 M
denosine 5-diphosphate (ADP), as previously described
24). The extent of aggregation was defined as the maximal
mount of light transmission reached within 6 min after the
gonist addition. The RPFA is a point-of-care system that
uantitatively measures the ability of platelets to agglutinate
brinogen-coated beads (25). Results were expressed as
latelet activation units and percentage of baseline.
tatistical analysis. Patient demographics, platelet func-
ion data, and coagulation tests are described using mean 
D. Thrombus area is described using mean  standard frror of mean (SEM). Intra-group comparisons were per-
ormed using paired two-tailed Student t tests. Inter-group
omparisons were performed using unpaired t tests and the
ann-Whitney non-parametric tests. Categorical variables
ere compared with the chi-square test. Analyses were
erformed using SPSS version 10 statistical software (SPSS
nc., Chicago, Illinois), and statistical significance was
onsidered as p  0.05.
ESULTS
he characteristics of the patient populations are outlined in
able 1. There were no significant differences in any of the
linical parameters between the two groups. Table 2 presents
he complete blood count parameters and coagulation tests.
ntra-group differences between the baseline and post-
ptifibatide samples were observed only in the hemoglobin
evel of group 1 (a decrease from 14.5  2.1 to 13.9  2.0
m/dl, p  0.01, both within normal range). Inter-group
ifferences were observed in the aPTT and anti-Xa levels. As
xpected, group 2 (treated by UFH) had significantly higher
PTT levels (28.2 4.4 s and 29.8 4.6 s in group 1 vs. 58.9
21.5 s and 52.4  10.4 s in group 2, p  0.001), whereas
roup 1 (treated by enoxaparin) exhibited higher levels of
nti-Xa activity (0.85  0.2 and 0.84  0.2 IU/ml in group 1
s. 0.57  0.1 and 0.55  0.1 IU/ml in group 2, p  0.001).
n group 2, at the second time point (on arrival at the
atheterization laboratory and post-eptifibatide), all patients
ere within the recommended aPTT range (at least 45 s),
xcept for one patient who had an aPTT level of 42.2 s.
ctivated clotting time values at the second time point were
28.2  6.2 s in group 1 and 179.7  21.8 s in group 2 (p 
.001).
The results of platelet function tests are outlined in Table
. In both groups, marked reductions in platelet function
ere achieved after eptifibatide (p  0.0001 for baseline vs.
ost-eptifibatide in all tests). Differences between the
roups in the extent of platelet function reduction were not
ignificant.
Total thrombus formation is presented in Figure 1. The
dministration of eptifibatide significantly reduced throm-
us formation in both groups. The antithrombotic effect
as observed at both high and low shear rates (p  0.0001
able 1. Clinical Characteristics
Group 1
(n  13)
Group 2
(n  13)
ge (yrs) 60.2  11.2 59.4  13.1
ales, n (%) 11 (84.6%) 12 (92.3%)
iabetes, n (%) 5 (38.5%) 4 (30.8%)
yperlipidemia, n (%) 9 (69.2%) 8 (61.5%)
ypertension, n (%) 9 (69.2%) 7 (53.8%)
urrent smoking, n (%) 4 (30.8%) 3 (23.1%)
nstable angina, n (%) 4 (30.8%) 2 (15.4%)
on–ST-elevation MI, n (%) 9 (69.2%) 11 (84.6%)
revious MI, n (%) 3 (23.1%) 4 (30.8%)
I  myocardial infarction.or both groups at both shear rates). However, the reduc-
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March 17, 2004:966–71 Eptifibatide Combined With Enoxaparin or Heparinions achieved in group 1 were significantly higher than
hose achieved in group 2 (HSR: 75.6% reduction from
0,845  1,279 m2 to 2,647  507 m2 in group 1 vs.
3.9% reduction from 12,878  1,258 m2 to 4,648  340
m2 in group 2, p  0.01; LSR: 79.7% reduction from
,753 542 m2 to 1,576 240 m2 in group 1 vs. 66.1%
eduction from 8,098  1,281 m2 to 2,747  273 m2 in
roup 2, p  0.0001). There were no significant differences
n the absolute baseline values of thrombus area at HSR or
SR between the two groups. Photomicrographs of total
hrombus formation in a representative patient from group
are shown Figure 2.
To investigate the contribution of fibrin deposition to
hrombus formation, we quantified fibrin area in both
roups. Fibrin deposition at HSR in group 1 decreased from
,276  1,033 m2 at baseline to 3,064  767 m2
ost-eptifibatide (57.9% decline, p  0.0001). In group 2,
brin deposition decreased from 8,081  2,039 m2 at
aseline to 4,093  1,009 m2 after the eptifibatide bolus
49.4% decline, p  0.0001). Although the reduction in
brin deposition achieved in group 1 was higher, the
ifference between the groups did not reach statistical
ignificance.
ISCUSSION
he current study compared the antithrombotic efficacy of
ptifibatide administered to ACS patients receiving either
noxaparin or UFH. Both therapeutic combinations in-
uced marked reductions in platelet aggregation and
latelet-thrombus formation. However, eptifibatide admin-
stered with enoxaparin was associated with a significantly
igher reduction in thrombus formation. This combination
herapy, therefore, appears to exert a more potent anti-
hrombotic effect than eptifibatide administered with UFH
n the doses tested.
n vitro and ex vivo effects of UFH and LMWH. In vitro
nd ex vivo studies have demonstrated that UFH causes
nhanced platelet activation (19,26,27). Unfractionated
Table 2. Results of Complete Blood Count an
Group 1 (n  13
Baseline Post-E
Hg (gm/dl) 14.5  2.1* 13.9
Plt (1,000/l) 240.1  57.5 235.9
Fibr (mg/dl) 499.3  133.3 510.6
INR 1.0  0.1 1.0
aPTT (s)† 28.2  4.4 29.8
Anti-Xa (IU/ml)† 0.85  0.2 0.84
TAT (g/l) 10.0  10.7 11.5
F1.2 (nmol/l) 1.4  0.4 1.6
Data presented as mean  SD.
*p  0.01, for baseline vs. post-eptifibatide in the specific
baseline and post-eptifibatide values.
Anti-Xa  anti-factor Xa activity; aPTT  activated par
fragment 1  2; Hg  hemoglobin; INR  international n
complex.eparin administrated to coronary patients or ex vivo addi-ion of UFH to blood from normal volunteers resulted in
ctivation of GP IIb/IIIa receptors, increased expression of
-selectin, and enhanced platelet aggregation with low
oncentrations of agonists (19,26–28). The mechanism
esponsible for the UFH-induced platelet activation may be
ts binding to the platelet integrin alphaIIb-beta3 resulting
n increased fibrinogen binding to the integrin and, there-
ore, enhanced fibrinogen binding to the activated platelet
29). In contrast with UFH, LMWH has been shown to
ave a more predictive anticoagulant effect with only minor
ffects on platelet activation (26,27). Furthermore, admin-
stration of LMWH, but not UFH, prevented repetitive
latelet-dependent thrombus formation in a stenosed canine
oronary artery model (30).
latelet effects of other GP IIb/IIIa inhibitors with UFH
r LMWH. The reported increased platelet reactivity as-
ociated with UFH could be the responsible mechanism for
he relatively reduced antithrombotic activity of eptifibatide
dministered with UFH when compared with the combi-
ation with enoxaparin in the current study. Other groups
ave reported similar observations on the variability and
latelet inhibitory effects of other GP IIb/IIIa inhibitors
hen combined with UFH or LMWH. Administration of
irofiban or abciximab with LMWH resulted in lesser
ariability and a trend towards greater inhibition of platelet
ggregation, as compared with the combination with UFH
15,18). Furthermore, coadministration of tirofiban or ab-
iximab with UFH attenuated the inhibition of
brinogen-GP IIb/IIIa receptor binding achieved without
FH (18). This attenuation was not demonstrated when
ombining these GP IIb/IIIa inhibitors with LMWH (18).
agulation Tests
Group 2 (n  13)
atide Baseline Post-Eptifibatide
.0* 13.8  1.5 13.7  1.5
3.7 223.5  43.6 233.2.1  50.6
23.9 538.9  136.0 583.2  183.3
.1 1.1  0.1 1.0  0.1
.6 58.9  20.9 52.4  10.4
.2 0.57  0.1 0.55  0.1
1.6 9.0  9.6 8.2  6.5
.6 1.8  1.0 1.8  0.8
†p  0.001, for differences between the two groups in both
romboplastin time; Fibr  fibrinogen; F1.2  prothrombin
ized ratio; Plt  platelets; TAT  thrombin-antithrombin
able 3. Results of Platelet Function Tests*
Group 1 (n  13) Group 2 (n  13)
0 M ADP aggregation 89.7% 85.5%
0 M ADP aggregation 83.0% 77.9%
PFA 94.7% 92.9%
ifferences between the two groups were not significant. *Expressed as percent
nhibition from baseline.d Co
)
ptifib
 2
 4
 1
 0
 4
 0
 1
 0
group;
tial th
ormalADP  adenosine 5-diphosphate; RPFA  rapid platelet function analyzer.
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Eptifibatide Combined With Enoxaparin or Heparin March 17, 2004:966–71imilarly, UFH induced a reduction in the extent of platelet
nhibition produced by abciximab (19). However, this re-
uction was only present at abciximab doses that induced
artial platelet inhibition, and not when abciximab induced
80% platelet aggregation inhibition (19). This observation
ay explain the lack of significant differences in platelet
ggregation between our two treatment groups. Eptifibatide
t a dose of 180 g/kg bolus, followed by 2.0 g/kg/min
nfusion, has been consistently shown to induce platelet
ggregation inhibition80% (31–33). This marked platelet
nhibitory effect may have overshadowed subtle differences
n platelet aggregation between the two combination groups
n our study. Microscopic evaluation of platelet-thrombus
ormation under severe arterial injury conditions and at
arious shear rates may represent a more physiologic and
ensitive method for assessment of therapeutic antithrom-
otic effects.
ffect on fibrin deposition. Treatment with abciximab has
een shown to reduce both platelet aggregates and the fibrin
ayer of the thrombus when using a perfusion flow chamber
odel (34). We have also observed, apart from a marked
eduction in total thrombus formation, a decline in fibrin
eposition after eptifibatide administration in both groups
57.9% reduction when eptifibatide was combined with
noxaparin and 49.4% reduction when combined with
FH). Platelet aggregates facilitate thrombin generation by
igure 1. (A) Total thrombus area (m2) at high shear rate (HSR) and low
hear rate (LSR) in the enoxaparin-eptifibatide group, and (B) the UFH-
ptifibatide group. Data presented as mean  SEM. In both groups and at
oth shear rates, highly significant differences were observed between the
aseline value and the post-eptifibatide value (p  0.0001). However, the
eductions achieved in group 1 were significantly higher than those achieved in
roup 2 (p  0.01 for inter-group differences at HSR, p  0.0001 for LSR).
olid bars  baseline; open bars  post-eptifibatide.roviding a phospholipid surface on which coagulation eeactions occur efficiently (35). The reduction in fibrin
eposition after eptifibatide administration is explained by a
ecrease in the platelet mass available for thrombin forma-
ion as a result of inhibition of platelet aggregation. A direct
ffect of eptifibatide on thrombin seems unlikely because, as
reviously observed (36), no reduction in thrombin forma-
ion (F1.2) or TAT occurred after eptifibatide administra-
ion, and furthermore, eptifibatide therapy has been shown
ot to prolong ACT (37).
tudy limitations. Our study is limited by the small
umber of patients in each group. However, because each
atient’s baseline value served as his own control, highly
ignificant intra-group differences could be obtained. The
ignificant differences observed between the two groups in
otal thrombus formation are further emphasized given the
elatively small patient number. The study was not random-
zed, although we enrolled consecutive patients, and the
emographic and clinical characteristics of the two groups
ere similar.
The results of the current study support the recent
ndings of clinical trials evaluating combination therapy
ith small molecule GP IIb/IIIa inhibitors and enoxaparin
n ACS patients (16,17). Both tirofiban and eptifibatide in
ombination with enoxaparin have been shown to reduce
arameters of ischemia as compared with their combination
ith UFH (16,17). The combination of GP IIb/IIIa inhib-
tors with enoxaparin has also been shown to be safe
12–17). Given the results of the recent clinical efficacy trials
nd our findings regarding antithrombotic activity, the
ombination of eptifibatide with enoxaparin appears to exert
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